gr1803
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2022 (NCT07102706)
Timeline
Indications
Studied for
Mechanism of action
CD3E activator
- BCMABINDING AGENT
BCMA binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07090954 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Government of China |
| NCT06952075 | Phase 2 | Apr 24, 2025 | Government of China |
| NCT06566547 | Phase 2 | Aug 26, 2024 | Government of China, Zhejiang University |
| NCT07102706 | Phase 1/Phase 2 (Phase 2) | May 27, 2022 | Government of China, Zhejiang University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 4 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1